Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04522544
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
Overview
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Contacts
Arndt Vogel, Prof. Dr.
vogel.arndt@mh-hannover.de
+49 511 5326 ext 760
Johanna Riedel, Dr.
riedel.johanna@ikf-khnw.de
+49 7601 ext 4635
ClinicalTrials.gov
NCT04522544Drug / Compound
Isotope(s):
YTTRIUM-90
Radioisotope: Y-90
Theranostic Role: Therapeutic Agent, SPECT Imaging & PET Imaging
T1/2 (Half-Life): 2.7 Days
Decay Mode: BETA
Energy: max 2.2 MeV
Range: In Tissue: Avg 2.5 mm, Max 11 mm; In Air: 35 feet
Decay Daughters: Zr90 (Stable)
Status: FDA Approvals: SIR-SPHERES® (2000), THERASPHERES® (2021)
Target(s):
Share your feedback
Help us improve your experience